Logo image of INBS

INTELLIGENT BIO SOLUTIONS IN (INBS) Stock Fundamental Analysis

NASDAQ:INBS - Nasdaq - US36151G6008 - Common Stock - Currency: USD

1.77  -0.06 (-3.28%)

After market: 1.82 +0.05 (+2.82%)

Fundamental Rating

3

INBS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 187 industry peers in the Health Care Equipment & Supplies industry. While INBS seems to be doing ok healthwise, there are quite some concerns on its profitability. INBS has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

INBS had negative earnings in the past year.
In the past year INBS has reported a negative cash flow from operations.
INBS had negative earnings in each of the past 5 years.
INBS had a negative operating cash flow in each of the past 5 years.
INBS Yearly Net Income VS EBIT VS OCF VS FCFINBS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

With a Return On Assets value of -107.08%, INBS is not doing good in the industry: 81.82% of the companies in the same industry are doing better.
The Return On Equity of INBS (-200.70%) is worse than 74.33% of its industry peers.
Industry RankSector Rank
ROA -107.08%
ROE -200.7%
ROIC N/A
ROA(3y)-81.21%
ROA(5y)-80.72%
ROE(3y)-175.72%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
INBS Yearly ROA, ROE, ROICINBS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K 2K 2.5K

1.3 Margins

The Gross Margin of INBS (58.81%) is comparable to the rest of the industry.
INBS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 58.81%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INBS Yearly Profit, Operating, Gross MarginsINBS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -1M -2M -3M

More info and screens

4

2. Health

2.1 Basic Checks

INBS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for INBS has been increased compared to 1 year ago.
Compared to 5 years ago, INBS has more shares outstanding
INBS has a better debt/assets ratio than last year.
INBS Yearly Shares OutstandingINBS Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
INBS Yearly Total Debt VS Total AssetsINBS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

Based on the Altman-Z score of -10.23, we must say that INBS is in the distress zone and has some risk of bankruptcy.
INBS has a worse Altman-Z score (-10.23) than 80.75% of its industry peers.
There is no outstanding debt for INBS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -10.23
ROIC/WACCN/A
WACC8.82%
INBS Yearly LT Debt VS Equity VS FCFINBS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M 15M

2.3 Liquidity

A Current Ratio of 1.12 indicates that INBS should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.12, INBS is doing worse than 86.63% of the companies in the same industry.
A Quick Ratio of 0.97 indicates that INBS may have some problems paying its short term obligations.
INBS's Quick ratio of 0.97 is on the low side compared to the rest of the industry. INBS is outperformed by 78.07% of its industry peers.
Industry RankSector Rank
Current Ratio 1.12
Quick Ratio 0.97
INBS Yearly Current Assets VS Current LiabilitesINBS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

6

3. Growth

3.1 Past

INBS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 96.01%, which is quite impressive.
Looking at the last year, INBS shows a small growth in Revenue. The Revenue has grown by 3.87% in the last year.
INBS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 589.28% yearly.
EPS 1Y (TTM)96.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.18%
Revenue 1Y (TTM)3.87%
Revenue growth 3Y16.26%
Revenue growth 5Y589.28%
Sales Q2Q%-11.54%

3.2 Future

INBS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 44.75% yearly.
INBS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 150.78% yearly.
EPS Next Y65.94%
EPS Next 2Y44.75%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year177.96%
Revenue Next 2Y150.78%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
INBS Yearly Revenue VS EstimatesINBS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 5M 10M 15M 20M 25M
INBS Yearly EPS VS EstimatesINBS Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 0 -50 -100 -150

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for INBS. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 4.96, which indicates a rather cheap valuation of INBS.
98.93% of the companies in the same industry are more expensive than INBS, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 35.19. INBS is valued rather cheaply when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 4.96
INBS Price Earnings VS Forward Price EarningsINBS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INBS Per share dataINBS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

INBS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as INBS's earnings are expected to grow with 44.75% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y44.75%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

INBS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INTELLIGENT BIO SOLUTIONS IN

NASDAQ:INBS (7/11/2025, 8:24:27 PM)

After market: 1.82 +0.05 (+2.82%)

1.77

-0.06 (-3.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)N/A N/A
Inst Owners12.83%
Inst Owner Change0%
Ins Owners0.79%
Ins Owner Change0%
Market Cap12.23M
Analysts85.71
Price Target12.24 (591.53%)
Short Float %8.98%
Short Ratio4.91
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-76.04%
Min Revenue beat(2)-78.54%
Max Revenue beat(2)-73.53%
Revenue beat(4)0
Avg Revenue beat(4)-63.33%
Min Revenue beat(4)-78.54%
Max Revenue beat(4)-50.1%
Revenue beat(8)0
Avg Revenue beat(8)-44.11%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 4.96
P/S 4.17
P/FCF N/A
P/OCF N/A
P/B 2.39
P/tB 9.34
EV/EBITDA N/A
EPS(TTM)-2.56
EYN/A
EPS(NY)0.36
Fwd EY20.17%
FCF(TTM)-1.51
FCFYN/A
OCF(TTM)-1.51
OCFYN/A
SpS0.42
BVpS0.74
TBVpS0.19
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -107.08%
ROE -200.7%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 58.81%
FCFM N/A
ROA(3y)-81.21%
ROA(5y)-80.72%
ROE(3y)-175.72%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.31
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.12
Quick Ratio 0.97
Altman-Z -10.23
F-Score3
WACC8.82%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)96.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.18%
EPS Next Y65.94%
EPS Next 2Y44.75%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)3.87%
Revenue growth 3Y16.26%
Revenue growth 5Y589.28%
Sales Q2Q%-11.54%
Revenue Next Year177.96%
Revenue Next 2Y150.78%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-2.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-22.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-22.25%
OCF growth 3YN/A
OCF growth 5YN/A